Recently, Dr. Molly He joined Foresite Capital as a venture partner. The healthcare growth equity firm’s chief executive officer, Jim Tananbaum, was happy with her inclusion to the company. Dr. He brings with her 15 years of experience in pharmaceutical and genomic research and development. Previously, the scientist worked for Illumina as a senior director.
Speaking after Dr. He’s acceptance to join the Foresite Capital, Jim Tananbaum said that the company would benefit from her extensive knowledge and experience in the industry. He added that Dr. He is a respected researcher in the field of next-generation sequencing. He believes that the scientist’s expertise in genomics and drug development will play an integral role in the growth of Foresite Capital. The company is planning to continue diversifying its portfolio to include more transformational companies.
In her previous position, Dr. He was in charge of the company’s global protein reagent innovations and improvements. Her visionary leadership helped the company to become a world leader in the field. Before joining Illumina, Dr. He worked for Pacific Biosciences. At the biotech company, she was the head of protein sciences. She is credited for developing the company’s single molecular real-time sequencing technology. The executive leader has worked in the pharmaceutical industry for over ten years.
Dr. He said that she was honored to join Foresite Capital. According to her, the company has a seasoned and dynamic team. She was optimistic that they would enhance the firm’s next-generation sequencing portfolio. In addition, Dr. Molly praised the strategic investments made by Foresite Capital. She added that such investments will revolutionize the healthcare industry.
Foresite Capital is a San Francisco-based investment company. The corporation invests in emerging healthcare companies. Owing to the increased demand for its products and services, the entity has opened an office in New York.
About Jim Tananbaum
Jim Tananbaum is the managing director of Foresite Capital. The executive leader has been working for the company since 2010. Over the years, he has helped the company to invest in promising healthcare companies.
Jim is also a shrewd entrepreneur. He is the brain behind two successful corporations, Prospect Venture Partners and Theravance. Jim is a partner at Sierra Ventures. Tananbaum is a graduate of three prestigious institutions, which are Harvard University, Massachusetts Institute of Technology (MIT), and Yale University. More details can be found on Bloomberg.